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Brief Communications
MicroRNAs Regulate Human Brain Endothelial Cell-Barrier
Function in Inflammation: Implications for Multiple
Sclerosis
Arie Reijerkerk,1* M. Alejandro Lopez-Ramirez,2* Bert van het Hof,1 Joost A.R. Drexhage,1WouterW. Kamphuis,1
Gijs Kooij,1 Joost B. Vos,3 Tineke C.T.M. van der Pouw Kraan,3 Anton J. van Zonneveld,4 Anton J. Horrevoets,3
Alexandre Prat,5 Ignacio A. Romero,2† and Helga E. de Vries1†
1Blood–Brain Barrier Research Group, Molecular Cell Biology and Immunology, Neuroscience Campus Amsterdam, VU University Medical Center, 1007
MB Amsterdam, The Netherlands, 2Department of Life, Health & Chemical Sciences, The Open University, Milton Keynes MK7 6AA, United Kingdom,
3Molecular Cell Biology and Immunology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands, 4Department of Nephrology and
Einthoven Laboratory for Experimental Vascular Research, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands, and 5Neuroimmunology
Research Laboratory, Centre of Excellence in Neuromics, CHUM-Notre-Dame Hospital, Faculty of Medicine, Universite´ de Montre´al, Montre´al, Quebec H2L
4M1, Canada
Blood–brain barrier (BBB) dysfunction is a major hallmark of many neurological diseases, including multiple sclerosis (MS). Using a
genomics approach, we defined a microRNA signature that is diminished at the BBB of MS patients. In particular, miR-125a-5p is a key
regulator of brain endothelial tightness and immune cell efflux. Our findings suggest that repair of a disturbed BBB throughmicroRNAs
may represent a novel avenue for effective treatment of MS.
Introduction
The blood–brain barrier (BBB) tightly controls the homeostasis
of the CNS and actively limits entry of blood-borne molecules
and circulating leukocytes. In essence, the BBB is formed by spe-
cialized endothelial cells sealed together by intercellular tight
junction protein complexes. Although mature astrocytes are
not needed for BBB induction (Daneman et al., 2010), these
cells are essential in the maintenance of the barrier function
through the release of soluble mediators (Abbott et al., 2006;
Alvarez et al., 2011). Disruption and immune activation of the
BBB are central and early features of multiple sclerosis (MS), a
chronic inflammatory disorder of the CNS (Neuwelt et al.,
2008, 2011; Zlokovic, 2008). Compromised function of the
BBB is also a key early event in the pathogenesis of several
neurodegenerative disorders with an inflammatory compo-
nent, such as Alzheimer’s disease and Parkinson’s disease.
Proinflammatory cytokines, such as TNF and IFN secreted
by activated leukocytes and/or CNS-resident cells, are consid-
ered to mediate changes in gene expression in brain endothe-
lial cells toward an “inflamed ” phenotype. Indeed, increased
permeability and expression of cell-adhesion molecules on the
brain endothelium allow the trafficking of inflammatory
agents and circulating leukocytes into the CNS, leading to
demyelination and axonal loss (Lassmann et al., 2007;
Larochelle et al., 2011). An understanding of the underlying
mechanisms of barrier disruption in MS may lead to the de-
velopment of novel and selective routes of intervention to
prevent the influx of inflammatory cells into the CNS.
MicroRNAs, which are endogenous noncoding small RNAs,
are now recognized to play a critical role in key cellular functions
by specifically repressing gene expression (Filipowicz et al.,
2008). Importantly, altered microRNA expression levels have
been demonstrated in a number of CNS pathologies, including
brain tumors, neurodegeneration, and MS (He´bert and De
Strooper, 2009;O’Connell et al., 2010; Junker et al., 2011; Smits et
al., 2012). Several microRNAs have been identified in endothelial
cells and they have been implicated in primary endothelial cell
function and angiogenesis (for review, see Sua´rez and Sessa,
2009; Bonauer et al., 2010). Thus far, it is not known whether
microRNAs play a role in BBB function, which was hypothe-
sized in the current study. Our novel data show that a set of
microRNAs modulates BBB function under normal and in-
flammatory conditions. Most importantly, levels of BBB-
associated microRNAs were diminished in isolatedMS patient
capillaries. Together, our findings uncover anunprecedented and
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exciting regulatorymechanismofbrain endothelial cell barrier func-
tion in health and disease and provide novel opportunities to treat
neurovascular-dependent brain diseases throughmicroRNAs.
Materials andMethods
Cells, cell culture, and materials. The human cerebral microvascular en-
dothelial cell line hCMEC/D3 (Weksler et al., 2005) was grown in Endo-
thelial Cell BasalMedium-2 (EGM-2, Lonza) supplemented with human
EGF, hydrocortisone, GA-1000, FBS, VEGF, human fibroblast growth
factor-B, R3-IGF-1, ascorbic acid, and 2.5% fetal calf serum. To obtain
astrocyte cultures, fetal tissue (cerebral hemispheres) was obtained at
17–23 weeks of gestation following Canadian Institute of Health
Research-approved guidelines. Human fetal astrocytes were used be-
tween postnatal days 2 and 4, and cultures were determined to be90%
pure, as determined by GFAP immunostaining. Astrocyte-conditioned
media (ACM)was harvested once aweek from confluent flasks of human
fetal astrocyte cultures. Anti-vascular endothelial-cadherin (anti-VE-
cadherin; clone F8) was from Santa Cruz Biotechnology. The tight junc-
tion protein zona occludens-1 was stained with rabbit anti-zona
occludens-1 from Zymed. Secondary antibodies Alexa Fluor 488 goat
anti-rabbit IgG and Alexa Fluor 555 goat anti-mouse IgG were from
Invitrogen.
MicroRNA profiling of inflamed brain endothelial cells. Human brain
endothelial (hCMEC/D3) cells were grown on collagen-coated six-well
plate tissue culture until confluence and then maintained for 72 h.
Subsequently, culture media was changed to EGM-2 with all the sup-
plements mentioned above with the exception of VEGF. After stimu-
lation with TNF and IFN using 10 ng/ml for 24 h, cells were washed
once with prewarmed HBSS. Total RNA was extracted using miR-
Neasy Mini Kit (Qiagen) according to the manufacturer’s protocols.
The quantity (NanoDrop 1000 spectrophotometer) and the quality
(2100 Bioanalyzer, RNA 6000 Pico LabChip; Agilent Technologies)
were assessed for each sample. Total RNA (100 ng) was labeled with
pCp-Cy3 using T4 RNA ligase (GE Healthcare) and the Agilent hu-
man microRNA microarray kit annotated in the Sanger miRbase (re-
lease 12.0) containing probes for 939 human microRNAs was
performed according to the Agilent’s microRNA microarray profil-
ing. GeneSpring GX 9 software (Agilent Technologies) was used for
value extraction. Statistical significance was determined by Student’s
t test for each microRNA probe.
MicroRNAprofiling of astrocyte-treated brain endothelial cells. For array
analyses hCMEC/D3 cells were incubated with 50% ACM in supple-
mented EGM-2 for 48 h. Total RNA was isolated from all cell lysates.
BeforemicroRNAprofiling, the RNA samples underwent quality control
by Agilent Bioanalyzer Picochip analysis (RNA integrity number, 9).
For microRNA expression analyses (Exiqon), 1 g of total RNA from
sample and reference was labeled with Hy3 and Hy5 fluorescent label,
respectively, using themiRCURYLNAArray power labeling kit (Exiqon)
following the procedure described by themanufacturer. TheHy3-labeled
samples and a Hy5-labeled reference RNA sample were mixed pairwise
andhybridized to themiRCURYLNAarray version 11.0 (Exiqon), which
contains capture probes targeting all microRNAs for human, mouse, or
rat registered in the miRBASE version 12.0 at the Sanger Institute. The
hybridization was performed according to the miRCURY LNA array
manual using a Tecan HS4800 hybridization station (Tecan). After hy-
bridization, the microarray slides were scanned and stored in an ozone-
free environment (ozone level,2.0 ppb) to prevent potential bleaching
of the fluorescent dyes. ThemiRCURY LNA arraymicroarray slides were
scanned using the Agilent G2565BAMicroarray Scanner System (Agilent
Technologies) and the image analysis was performed using the ImaGene
8.0 software (BioDiscovery). Generation and statistical analysis of mi-
croRNA expression profiles were performed similarly using R/Biocon-
ductor. Quantile normalization of intensities of individual spots was
followed by reference color adjustment and ratios of probes representing
the same microRNA were averaged. Differential expression of ACM-
treated versus control samples was determined by Baysian statistics t test
(Baldi and Long, 2001) andmultiple testing adjustment using Benjamini
and Hochberg’s method (Benjamini and Hochberg, 1995).
Isolation of MS capillaries. The tissues were obtained from The Neth-
erlands Brain Bank (NBB), Netherlands Institute for Neuroscience, Am-
sterdam. For all material, NBB obtained from donors a written informed
consent for brain autopsy and the use of the material and clinical infor-
mation for research purposes. Brain capillaries were isolated from
periventricular non-neurological patient tissue, periventricular normal-
appearing white matter, and periventricular MS lesions from postmor-
tem MS patients. After resection, the tissues were homogenized using
pestles and capillaries were separated from myelin and single cells using
dietheylaminoethyl–dextran gradient (15%; Sigma-Aldrich) centrifuga-
tion for 25 min at 2500 rpm without brake. Isolated capillaries were
washed on a 40mmeshed filter (BD Falcon) to remove red blood cells.
Finally, RNA was extracted with Trizol and stored in80°C. The capil-
laries were characterized by qPCR analysis of brain endothelial cellmark-
ers zona occludens-1, claudin-5, VE-cadherin, and P-glycoprotein; the
pericyte marker platelet-derived growth factor receptor-; and astrocyte
marker GFAP.
qPCR analysis of microRNA expression. The Universal cDNA Synthesis
Kit (Exiqon) was used for cDNA synthesis. Extracted RNAwas diluted to
5 g/l using RNase-free water. For each reaction, 2 l of diluted RNA
was added to a mixture of 2 l of 5 buffer, 4.5 l of RNase-free water,
1 l of enzyme mix, and 0.5 l of RNA spike-in. The samples were
incubated at 42°C for 1 h followed by heat inactivation at 95°C for 5min.
Samples were cooled to 4°C and stored at 20°C thereafter. The qPCR
was performed using the Pick-&-Mix microRNA PCR Panel using the
LNA microRNA PCR primer sets for the indicated 11 microRNAs (Ex-
iqon). Three independent samples per plate were tested. The cDNA was
diluted 1:100 in RNase-free water. Per well, 5l of sample and 5l of 2
SYBRgreen mastermix were added and plates were then sealed and cen-
trifuged. qPCRwas performed on anApplied BiosystemsViiA 7machine
for 40 cycles, which consisted of two steps at 95°C for 10 s and 60°C for 1
min. Specificity of the PCRproduct was determined by amelting curve at
the end of the qPCR.
Lentiviral delivery of miR-125a-5p. The miR-125a-5p sequence was
obtained from the miR-Vec library (Voorhoeve et al., 2006) and ligated
between the NdeI and EcoRI restriction sites of pRRL-cPPT-CMV-X2-
PRE-SIN-IRES-eGFP vector (kindly provided by Dr. J. Seppen, Depart-
ment of Experimental Hepatology, AcademicMedical Center, Amsterdam,
TheNetherlands). Recombinant lentiviruses were produced by cotransfect-
ing subconfluent HEK293T cells with the specific expression plasmids and
packaging plasmids (pMDLg/pRRE, pRSV-Rev, and pMD2G) using cal-
cium phosphate as a transfection reagent. HEK293T cells were cultured in
DMEM, supplemented with 10% FCS and 1% penicillin/streptomycin, in a
37°C incubatorwith5%CO2. Infectious lentiviruseswerecollected48hafter
transfection. The supernatant was centrifuged to remove cell debris and
stored at80°C. Overexpression efficiency in hCMEC/D3 cells was deter-
mined by qPCR.
Transfections. hCMEC/D3 cells were transfected using Amaxa Tech-
nology (Lonza). Per condition, 15 cm2 of 80–90% confluent cells were
trypsinized and transfected with siRNA against miR-125a-5p (2.5 l of
25MmiRCURY LNAmicroRNA Inhibitor, Exiqon) or scrambled RNA
(2.5l of 25MmiRCURY LNAmicroRNA Inhibitor Negative Control,
Exiqon). The transfection was performed with the 4D-Nucleofector Sys-
tem and P5 Primary Cell Solution Kit (Amaxa, Lonza), according to the
manufacturer’s protocol. After transfection, the cells were resuspended
in RPMI-1640 medium supplemented with penicillin (100 U/ml) and
streptomycin (100 g/ml) for 5 min, and subsequently seeded on
collagen-coated electrical cell-substrate impedance-sensing (ECIS) ar-
rays with additional supplemented EGM-2 medium. Knockdown of
miR-125a-5p was assessed by qPCR.
ECIS assay. ECISModel 1600R (Applied BioPhysics) was used tomea-
sure the transendothelial electric resistance of hCMEC/D3 cell monolay-
ers in real time as described previously (Keese et al., 2004). We seeded
100,000 cells onto each well of an 8W10 ECIS array coated with colla-
gen. Impedance was measured at 6000 Hz in real time. Cells were treated
with a 1:1 mixture of ACM and EGM-2 containing 2.5% FCS or with 10
ng/ml TNF and IFN immediately after seeding. Lentiviral transduc-
tion of microRNA-125a was performed directly after seeding in the ECIS
array.
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Statistical analysis. Statistical analysis was performed with the Stu-
dent’s t test (Prism 4.0; GraphPad Software), and results were considered
significant if p was0.05.
Results
Here we exploredwhethermicroRNAs control BBB function and
its immunoquiescence in MS. First, microRNA expression pro-
filing indicated that exposure of cultured brain endothelial cells
to inflammatory mediators significantly changed the expression
level of 107microRNAs (Fig. 1A). Of note,most (98 of 107) of the
differentially expressed microRNAs were downregulated by
TNF and IFN treatment, which was also shown to impair bar-
rier function (Fig. 1B). Next, as a means to identify barrier-
related microRNAs, we cultured brain endothelial cells in the
presence of astrocyte-released factors. Continuous treatment of
brain endothelial monolayers with conditioned media of cul-
tured astrocytes for 48 h induced a tighter barrier in cultured
brain endothelial cells (Fig. 1D) and significantly changed the
expression level of 365 microRNAs (Fig. 1C). In this case, 278 of
365 of the differentially expressed microRNAs were increased in
the brain endothelial cells by astrocyte-released factors, suggest-
ing that microRNA-mediated induction of BBB properties is
largely due to repression of protein synthesis within the brain
endothelium. Remarkably, the overlay of the microRNA expres-
sion profiles between TNF/IFN (i.e., barrier-reducing) and
astrocyte factor (i.e., barrier-inducing) treatments revealed that
the expression of 50 of the 55 microRNAs regulated by both
treatments changed in opposite directions. MicroRNAs de-
creased by barrier-reducing TNF/IFN treatment were en-
hanced by barrier-inducing astrocyte factors and vice versa (Fig.
1E). These data strongly suggest a potential and important func-
tion of a set ofmicroRNAs controlling the balance between a tight
and leaky or inflamed BBB.
To specifically identify microRNAs involved in the immune-
activated and dysfunctional BBB as observed in MS, we next as-
sessed the expression level of this particular set of BBB-related
microRNAs. Quantitative PCR analyses of 11 microRNAs with
the highest differential in expression levels when comparing
barrier-enhancing versus barrier-reducing stimuli (Fig. 1E, col-
ored dots) was done using freshly isolated brain capillaries from
MS lesion areas and normal-appearing white matter in MS pa-
tients (Fig. 2A, patient characteristics). Freshly isolated brain cap-
illaries comprised brain endothelial cells as indicated by zona
Figure 1. Brain endothelial microRNAs are deregulated in inflammation in vitro. A, C, Heat map of differential microRNA expression in (A) TNF and IFN (10 ng/ml for 24 h) and (C) astrocyte
factor-treated (ACM, 50% v/v, 48 h) hCMEC/D3 cells. Purple indicates relatively higher expressed microRNAs. Yellow indicates relatively lower expressed microRNAs. B, ECIS analysis of control and
TNF/IFN-treated hCMEC/D3 cells. Maximal resistance in control: 1014  41.2 ; TNF/IFN: 667.6  41.2 , n  4, p  0.001 by Student’s t test. D, ECIS analysis of control and
astrocyte-derived factor-treated hCMEC/D3 cells. Maximal resistance in control: 1673 1.1; ACM (50% v/v): 2008 58.8, n 3, p 0.001 by Student’s t test. Error bars represent the
mean SEM. E, Representation of commonmicroRNAs regulated after ACM and TNF/IFN-treatment in hCMEC/D3 cells.
Reijerkerk, Lopez-Ramirez et al. •MicroRNAs and the Inflamed Blood–Brain Barrier J. Neurosci., April 17, 2013 • 33(16):6857–6863 • 6859
occludens-1, claudin-5, P-glycoprotein,
and VE-cadherin expression and contained
minor amounts of astrocytes (GFAP and
GFAP) and pericytes (platelet-derived
growth factor receptor-) (Fig. 2B). Most
strikingly, all the microRNAs selected ac-
cording to their opposing regulation in
TNF/IFN and astrocyte factor-treated
brain endothelial cells were reduced in
brain capillaries in MS lesions (Fig. 2C).
These findings indicate that the currently
identified microRNAs may represent po-
tential and novel mechanisms by which
BBB function is altered in MS. Of note, it
was reported before that miR-125a-5p in
particular can regulate inflammatory pro-
cesses (Chen et al., 2009; Li et al., 2010;
Zhao et al., 2010). The decreased ex-
pression of miR-125a-5p in MS lesions
was corroborated in brain endothelial cells
obtained from normal-appearing white
matter and active lesions of MS patients
through a laser capture approach (Fig. 2D).
Normally, the barrier function of the
brain endothelium is instigated by the
presence of specific cell–cell junction
complexes and a high endothelial resis-
tance to paracellular trafficking of ions
and other molecules. We therefore set out
to assess the contribution ofmiR-125a-5p
to the formation of a tight brain endothe-
lial barrier. Using cell lines overexpressing
miR-125a-5p, we determined that miR-
125a-5p significantly increased brain en-
dothelial cell barrier function, thereby
mimicking the function of astrocytes (Fig.
3A). Conversely, specific knockdown
of miR-125a-5p reduced the barrier-
enhancing effect of astrocytes without in-
fluencing barrier formation under control
conditions (Fig. 3B). Subsequent confocal
microscopy analyses revealed that cells
with increased levels of miR-125a-5p
formed thicker and more continuous
junctional complexes of VE-cadherin and
zona occludens-1, whereas the opposite
was found in cells with reduced levels of
miR-125a-5p (Fig. 2C). The altered ex-
pression levels of VE-cadherin was con-
firmed by Western blotting (data not shown).
In general, the brain endothelial cell barrier maintains im-
mune quiescence of the brain through the low expression of ad-
hesion molecules, such as intracellular cell adhesion molecule
(ICAM)-1, a cell adhesion molecule involved in vascular perme-
ability and leukocyte infiltration. However, under inflamed con-
ditions, as apparent during MS, brain endothelial cells strongly
upregulate cell adhesion molecules that in turn mediate the mi-
gration of leukocytes into the brain. Treatment of the brain en-
dothelium with the proinflammatory mediators TNF/IFN
caused a strong reduction ofmiR-125a-5p levels (Fig. 3D), which
in turn was associated with enhanced expression of the endothe-
lial cell adhesion molecule ICAM-1 and increased diapedesis of
leukocytes (Fig. 2E,F). Interestingly, overexpression of miR-
125a-5p in the brain endothelial cells reduced TNF-mediated
ICAM-1 expression and monocyte transmigration through the
brain endothelial cell barrier (Fig. 3E,F).
Discussion
Here, we are the first to show that microRNAs contribute to
modulation of BBB function. We assessed microRNA expression
in brain endothelial cells treated either with proinflammatory
cytokines known to impair BBB function or with astrocyte-
released factors that can strengthen BBB function.We found that
while a large number ofmicroRNAswere downregulated in brain
endothelial cells with impaired BBB function, strengthening BBB
function was generally associated with increased microRNA ex-
pression. Thus, we identified a microRNA signature that is cen-
Figure 2. Brain endothelial microRNAs are deregulated in MS patients. A, MS and non-neurological control patient character-
istics. B, Capillaries isolated from normal-appearing white matter were characterized for expression of brain endothelial cell
markers zona occludens-1, claudin-5, VE-cadherin, and P-glycoprotein; the pericytes marker platelet-derived growth factor
receptor-; and astrocyte marker GFAP at the mRNA level by qPCR analysis. Data show the relative abundance of the
indicated mRNA normalized to GAPDH SEM. C, qPCR analysis of microRNAs in brain capillaries isolated from brains of
non-neurological controls (blue), MS patient normal-appearing white matter (NAWM, green), and MS lesions (red). Data
show themean fold expression relative to control tissue SEM, n 4, *p 0.05, **p 0.005 by Student’s t test.D, qPCR
analysis of miR-125a-5p in brain endothelial cells isolated by laser capture microdissection from NAWM and MS lesions in
six individuals. Data show the relative abundance of miR-125a-5p normalized to the small nuclear RNA U6. p 0.03 by
paired Student’s t test.
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tral in the regulation of the balance
between a tight and leaky BBB.
In our study, the expression of miR-
125a-5p and many other microRNAs
were regulated in human brain endothe-
lial cells exposed to astrocyte factors.
Importantly, brain capillaries are sur-
rounded by and closely associated with the
perivascular endfeet of astrocytes and there
is now strong evidence that astrocytes can
induce many BBB features, leading to
tighter junctions (physical barrier), the ex-
pression and localization of specific
transporters, including P-glycoprotein
and glucose transporter-1 (transport bar-
rier), and specialized metabolic systems
(metabolic barrier; see reviewbyAbbott et
al., 2010). Astrocytes are able to secrete a
range of agents (Abbott et al., 2006) and
different research groups have attempted
to identify these soluble factors, which
may be responsible for the induction of
BBB properties in cultured brain endo-
thelial cells. Several of these astrocyte-
derived factors, including transforming
growth factor- (Garcia et al., 2004),
glial-derived neurotrophic factor (Iga-
rashi et al., 1999), angiotensin II (Wosik et
al., 2007), and angiopoietin 1 (Lee et al.,
2003) can induce different aspects of the
BBB phenotype in endothelial cells in
vitro. More recently, using a shotgun pro-
teomics and bioinformatics approach, oth-
ers have identified and classified the
proteins present in conditioned media of
cultured astrocytes (Dowell et al., 2009).
Future analyses are warranted to identify
the soluble factors that mediate mi-
croRNA responses in brain endothelial
cells.
Altogether, our data provide compel-
ling evidence pointing to an important
function for microRNAs at the BBB, in
particular during inflammation. In the
field of brain diseases, microRNAs are
rapidly moving to center stage as key regu-
lators of neuronal development and func-
tion as well as important contributors to
neurodegeneration (He´bert and De
Strooper, 2009; De Smaele et al., 2010). As
such, the functionality of microRNA inMS
is still largely unexplored. The first findings
in this area are, however, exciting. Recent
studies have revealed that microRNA pro-
files inperipheral bloodcells becomealtered
in MS, and that active and inactive MS le-
sions have distinct microRNA expression
patterns (Du et al., 2009; Junker et al., 2009,
2011). The deregulated microRNAs in MS
lesions seem to be associated with immune
responses, and might unleash local macro-
phages through downregulation of the self-
recognition signal CD47(Junker et al.,
Figure 3. Brain endothelial miR-125a-5p regulates barrier tightness and prevents leukocyte passage. A,B, Overexpression (A)
and knockdown (B) of miR-125a-5p in hCMEC/D3 cells significantly modulates barrier tightness in control (A) and ACM-treated
cells (B) as determined by ECIS (control: 809.3 48.9; miR-125a-5p: 948.5 18.7). C, VE-cadherin and zona occludens-
1(ZO-1) subcellular distribution in control cells, in miR-125a-5p-overexpressing hCMEC/D3 cells, and inmiR-125a-5p-knockdown
hCMEC/D3 cells. Scale bars, 25m. D, TNF treatment of hCMEC/D3 decreases the expression of miR-125a-5p as measured by
qPCR. Data show the abundance of miR-125a-5p normalized to the small nuclear RNA U6 relative to levels in control cells SEM,
n 3, *p 0.05, **p 0.005 by Student’s t test. E, Transendothelial migration of monocytes was studied in control hCMEC/D3
cells and in cellswithenhancedexpressionmiR-125a-5ppreviously treatedornotwithTNF. Dataareexpressedas thepercentage
of transmigrated monocytes and show the mean  SEM. F, ICAM-1 expression in control hCMEC/D3 cells and in cells with
enhancedexpressionofmiR-125a-5p in thepresenceor absenceof TNFasmeasuredby flowcytometry.Data are expressedas the
mean fluorescence intensity and show the mean SEM.
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2009). Such findings indicate thatMS is the effect of (auto)immune
responses mediated, at least partially, by microRNAs. In 2010, a
study published inNature (Du et al., 2009) showed that the expres-
sion of a TH-17 cell-associated microRNA, miR-326, is highly cor-
related with disease severity in patients with MS and in mice with
experimental autoimmune encephalomyelitis, amodel for brain in-
flammation widely used to study CNS demyelinating diseases, such
asMS.
Although themechanism of action and specificmRNA targets
of miR-125a-5p are largely unknown, others have shown that
miR-125a-5p has a role in different tumor types and inflamma-
tion. miR-125a-5p is decreased in non-small cell lung cancer
(Jiang et al., 2010), hepatocellular carcinoma (Murakami et al.,
2006), breast cancer (Guo et al., 2009), and medulloblastoma
(Ferretti et al., 2009). Low expression levels of miR-125a-5p were
associated with enhanced malignant potential of gastric cancer,
possibly through repression of ERBB2, leading to reduced
extracellular-signal regulated kinase 1/2 and Akt signaling (Scott
et al., 2007; Nishida et al., 2011). Other cancer-related mRNA
targets of miR-125a-5p are TrkC (Ferretti et al., 2009), the onco-
gene p53 (Zhang et al., 2009), human antigenR (Guo et al., 2009),
and cyclin-dependent kinase inhibitor 1A (Wu et al., 2010). Al-
though microRNAs have received increasing attention as regula-
tors that fine-tune the inflammatory response, much less is
known about the function of miR-125a-5p in inflammatory pro-
cesses. It is of interest that miR-125a-5p inhibits endothelin-1
expression in vascular endothelial cells (Li et al., 2010).
Endothelin-1 is a proinflammatory protein involved inmonocyte
diapedesis (Reijerkerk et al., 2012). Others previously showed
that miR-125a decreases the secretion of some inflammatory
cytokines (IL-2, IL-6, TNF-, and TGF-) by targeting the oxys-
terol binding protein-like 9 (Chen et al., 2009). Moreover, miR-
125a contributed to elevated inflammatory chemokine RANTES
(regulated on activation, normal T-cell expressed and secreted)
levels via targeting of KLF13 in systemic lupus erythematosus
(Zhao et al., 2010). The mechanism of action of miR-125a-5p in
the inflamed BBBwarrants further study. Finally, deregulation of
microRNAs contributes to many human diseases and there is
great interest in microRNAs as novel therapeutic targets or tools.
The direction toward therapeutic application has been set in an-
imal models to suppress liver cancer (He´bert and De Strooper,
2009) or chronic hepatitis C virus infection (Kota et al., 2009).
Importantly, our current data point to a significant andnovel role
of microRNAs in BBB functioning. Many neurological disorders
are associated with profound alterations in the vasculature of the
brain. Therapeutic application ofmicroRNAs, such asmiR-125a-
5p, potentially could re-establish normal functioning of the brain
vasculature in endothelial cell-based neurological diseases, in
particular MS.
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